|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 281, Issue 36, 26205-26215, September 8, 2006
Tumor Necrosis Factor-induced Long Myosin Light Chain Kinase Transcription Is Regulated by Differentiation-dependent Signaling EventsCHARACTERIZATION OF THE HUMAN LONG MYOSIN LIGHT CHAIN KINASE PROMOTER*![]() ![]() ![]() 1![]() ![]() ![]() 2
From the
Received for publication, March 7, 2006 , and in revised form, May 19, 2006.
Myosin light chain kinase (MLCK) is expressed as long and short isoforms from unique transcriptional start sites within a single gene. Tumor necrosis factor (TNF) augments intestinal epithelial long MLCK expression, which is critical to cytoskeletal regulation. We found that TNF increases long MLCK mRNA transcription, both in human enterocytes in vitro and murine enterocytes in vivo.5'-RACE identified two novel exons, 1A and 1B, which encode alternative long MLCK transcriptional start sites. Chromatin immunoprecipitation (ChIP) and site-directed mutagenesis identified two essential Sp1 sites upstream of the exon 1A long MLCK transcriptional start site. Analysis of deletion and truncation mutants showed that a 102-bp region including these Sp1 sites was necessary for basal transcription. A promoter construct including 4-kb upstream of exon 1A was responsive to TNF, AP-1, or NF B, but all except NF B responses were absent in a shorter 2-kb construct, and all responses were absent in a 1-kb construct. Electrophoretic mobility shift assays, ChIP, and site-directed mutagenesis explained these data by identifying three functional AP-1 sites between 2- and 4-kb upstream of exon 1A and two NF B sites between 1- and 2-kb upstream of exon 1A. Analysis of differentiating epithelia showed that only well differentiated enterocytes activated the 4-kb long MLCK promoter in response to TNF, and consensus promoter reporters demonstrated that TNF-induced NF B activation decreased during differentiation while TNF-induced AP-1 activation increased. Thus either AP-1 or NF B can up-regulate long MLCK transcription, but the mechanisms by which TNF up-regulates intestinal epithelial long MLCK transcription from exon 1A are differentiation-dependent.
Myosin light chain kinases (MLCKs)3 are essential regulators of actomyosin function (1). Mammalian MLCK is encoded by two separate genes; the first is expressed in skeletal and cardiac muscle whereas the second, smooth muscle MLCK, generates three different proteins, long MLCK, short MLCK, and telokin, as a result of tissue-specific transcription from separate promoters (1-6). Like all MLCKs, the 130-kDa smooth muscle, or short, MLCK includes a catalytic domain and a separate Ca2+-calmodulin-dependent regulatory domain.
Long MLCK is a 210-kDa protein originally identified in cultured cells, embryonic tissues, and endothelium (2, 4, 7, 8). It contains the same catalytic and regulatory domains as short MLCK but also includes an N-terminal extension that contains six immunoglobulin-like modules and two tandem actin binding domains (9). Long MLCK must therefore be transcribed from an upstream promoter, although this promoter has not been identified. Long MLCK is the principal form expressed in intestinal epithelial cells (8) and expression of long MLCK is increased by tumor necrosis factor (TNF) treatment of cultured intestinal epithelial monolayers (10, 11). These increases in MLCK protein expression are accompanied by increased myosin light chain phosphorylation which, in turn, leads to disruption of the epithelial barrier (12-14). This long MLCK-dependent disruption of epithelial barrier function is an important component of intestinal disease (15). For example, long MLCK knock-out mice are protected from TNF-dependent intestinal epithelial MLC phosphorylation, barrier loss, and diarrhea (16). Similar protection is conferred by pharmacological intestinal epithelial MLCK inhibition (16). While the functional significance of increased intestinal epithelial long MLCK expression has not been defined in humans, it is notable that intestinal epithelial cells of patients with inflammatory bowel disease also display increased long MLCK expression (17). This is remarkable, as inflammatory bowel disease patients are known to have epithelial barrier defects that can be corrected by anti-TNF therapy (18). Thus, inducible long MLCK expression may be a critical regulator of intestinal epithelial barrier function and disease pathogenesis. Despite data indicating the potential biological and therapeutic potential of harnessing inducible long MLCK expression, the factors that regulate this process are unknown. Using the model of TNF-induced long MLCK expression in intestinal epithelia, we now show this process to be caused by transcriptional activation. TNF increased long MLCK mRNA transcripts in cultured human intestinal epithelial cells in vitro and in mouse intestinal epithelial cells in vivo. Two novel human long MLCK transcriptional start sites, corresponding to novel exons, were identified and the promoter corresponding to one was cloned. Moreover, the sites necessary for basal and TNF-inducible transcription have been defined. Remarkably, the requirements for TNF-inducible long MLCK transcription differ in undifferentiated and well differentiated intestinal epithelial cells, suggesting that long MLCK transcription can be regulated by multiple mechanisms. These data therefore define regulation of long MLCK transcription under basal conditions as well as following cytokine stimulation and suggest that the factors responsible for long MLCK induction are dependent on cellular differentiation state.
Cell Culture and Cytokine TreatmentCaco-2BBE cells (19) expressing the intestinal Na+-glucose cotransporter SGLT1 (20) were maintained and cultured as monolayers as described previously (8). For studies of differentiation and cytokine responses, monolayers grown on Transwell semipermeable supports (Corning-Costar, Acton, MA) were used 3-14 days after reaching confluence, as indicated. Recombinant human IFN- and TNF (R&D Systems, Minneapolis, MN) were routinely added to the basal chamber without manipulating the apical media, as described previously (10). IFN- -priming was performed by incubation for 18 h with 10 ng/ml IFN- , and TNF was used at 2.5 ng/ml, both in the basal compartment (10). Animal Model7-10-week-old wild-type C57BL/6 female mice were injected intraperitoneally with either 5 µg of recombinant murine TNF (PeproTech Inc., Rocky Hill, NJ) in 200 µl of phosphate-buffered saline or with phosphate-buffered saline alone, as described previously (16). Animals were sacrificed 4 h after injection and jejunal epithelia isolated as previously described (16). Briefly, a section of intestine was opened length-wise, and washed at 4 °C in Ca2+- and Mg2+-free HBSS (CMF-HBSS), transferred to CMF-HBSS containing 10 mM dithiothreitol and 50 nM calyculin A (Calbiochem, San Diego, CA), incubated for 30 min at 4 °C, and transferred to a fresh tube containing CMF-HBSS with 1 mM EDTA and 50 nM calyculin A. After incubation at 4 °C for 1 h, epithelial cells were dislodged by vigorous shaking, harvested by centrifugation, and placed in TRIzol (Invitrogen, Carlsbad, CA) for mRNA analysis or SDS-PAGE sample buffer for immunoblot. Animal studies were carried out in accordance with National Institutes of Health guidelines under protocols approved by the Institutional Animal Care and Use Committee at The University of Chicago. 5' Rapid Amplification of cDNA Ends (5'-RACE)Total RNA was isolated chromatographically from Caco-2BBE cells (Qiagen, Valencia, CA), and mRNA was purified on poly-T beads (Qiagen). Antisense primer (5'-GAATCGTCCCATCTGTC-3') positioned within exon 4 was used for first-strand cDNA synthesis. Subsequent amplification was performed using the 5'-RACE system for rapid amplification of cDNA ends (Invitrogen). In brief, cDNA was tailed with recombinant TdT and linker (dC) oligonucleotide. 5'-RACE was performed by incubating with an aliquot of first-strand cDNA, a RACE primer positioned within exon 3 (5'-CCGCTGGTGATGGGTTGC-3'), and the abridged anchor primer. PCR conditions were initial denaturation at 94 °C for 3 min, 38 cycles of 30 s at 94 °C, 1 min at 58 °C, and 1 min at 72 °C. The final extension step at 72 °C was carried out for 10 min. The resulting products were cloned into pCR2.1-TOPO (Invitrogen) and sequenced to determine the transcriptional start site(s). In Silico Sequence AnalysisGenomic DNA sequences were downloaded from the NCBI data base. In silico transcription factor binding analysis was carried out using the TFSearch program with a threshold of 85. This program searches highly correlated sequence fragments versus the TFMATRIX transcription factor binding site profile data base within the TRANSFAC resources (21). Cloning and Vector ConstructionThe region from -4105 to -155bp, MLCK (4 kb), and from -4105 to -10 bp, MLCK(+145), relative to the long MLCK transcriptional start site within exon 1A was amplified from human genomic DNA using forward 5'-CCGCTCGAGTGCTATTCAAACAGGAATACAA-3' and reverse 5'-CCCAAGCTTCTCTGAACTGCAGCAGAGG-3' or 5'-GGGTGGACTGAGGAGGAAT-3' primers, respectively. The promoters were verified by direct sequencing and cloned into the pGL3-Basic luciferase vector (Promega, Madison, WI). The 2-kb, 1-kb, 500-bp, and 120-bp promoters were created using the same reverse primer as the 4-kb promoter, and the forward primers 5'-AAGAATGGAAATGACAGAGC-3', 5'-CACTGTTGCATCAGGGATTA-3', 5'-ATCCCTGATAGCCAGGAG-3', and 5'-GTGATGTACTCCTCCCAGCC-3', respectively. These PCR products were first cloned into pCR2.1-TOPO and subsequently sequenced and cloned into pGL3-Basic.
Deletion constructs were made by standard restriction digestion and ligation. The
Disruption of transcription factor binding sites was done by mutagenesis using the QuikChange site-directed mutagenesis kit (Stratagene). Sense oligonucleotides were: 5' Sp1, 5'-GTCCCAGAGTGATGTACTACGATCAGCCGCTCCCACATCC-3';3' Sp1, 5'-CTGATTTGGCTTTCCTTTACGACTTCCCACCCACCCAGG-3'; AP-1 (1), 5'-CTCCAGGGCTCTGCCCTATCAACTTAAGTACCTCCTAAAGGTCCTACC-3'; AP-1 (2), 5'-GACAATATGCATTTTACCACCAGCATAGCTAATACATAATAAACCTGGCATCCTCCTTCATCTC-3'; AP-1 (3), 5'-GCCCCACACCCAGAGTTTCTTCTTAATCAAGTCTGGGGTAGGACCCAATAAT-3'; AP-1 (4) 5'-CTCAACCTTGAGCCTGCACCAAGGGAACCTGGAGGACTTGTCAATACG-3'; NF
Transfection and Luciferase AssayPromoter constructs, pNF
Electrophoretic Mobility Shift AssaysFor protein-DNA binding reactions, 5 µg of HeLa nuclear extract protein (Promega) was incubated with 32P-labeled probe or unlabeled competitors for 30 min at room temperature in a 25-µl reaction containing gel shift binding buffer (Promega). Probes were double-stranded oligonucleotides with the sense sequence AP-1 (1), 5'-CTCTTGACTTAATCACCTCCTA-3'; AP-1 (2), 5'-CCAGCAGAGCTGACACATCAGAAA-3'; AP-1 (3), 5'-CAGAGTTTCTGATTCAGCAGGTCT-3'; AP-1 (4), 5'-AGCCTGCATCAGAGTCACCTGGAG-3'; NF Real Time RT-PCRCell extracts in TRIzol were sonicated, and RNA was extracted with chloroform, precipitated with isopropyl alcohol, and resuspended in diethyl pyrocarbonate-treated water. RNA was further purified using a RNeasy mini kit (Qiagen). cDNA was generated from 2 µg of RNA using Thermoscript reverse transcriptase (Invitrogen) and random hexamer primers in a 25-µl reaction. Long MLCK mRNA expression was determined by SYBR green real-time PCR through 50 cycles using the MyiQ Real-Time PCR Detection System (Bio-Rad). GAPDH was used as a reference. Primers were 5'-CACCGTCCATGAAAAGAAGAGTAG-3' and 5'-GAGAGGCCCTGCAGGAAGATGG-3' for detection of human long MLCK, 5'-GCGTGATCAGCCTGTTCTTTCTAA-3' and 5'-GCCCCATCTGCCCTTCTTTGACC-3' for detection of murine long MLCK, and 5'-CTTCACCACCATGGAGAAGGC-3' and 5'-GGCATGGACTGTGGTCATGAG-3' for detection of human and murine GAPDH. SDS-PAGE and Immunoblot AnalysisCell lysates were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes, as described previously (10, 16). MLCK was detected using the K36 monoclonal antibody (Sigma). After incubation with peroxidase-conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA), blots were visualized by enhanced chemiluminescence as described previously. Densitometry of immunoblot data were performed using Metamorph 6.2 (Universal Imaging Corp., Downingtown, PA).
Chromatin ImmunoprecipitationChromatin immunoprecipitation assays were performed using the EZChIP kit (Upstate Group, Charlottesville, VA). Caco-2 cells grown to differentiation were fixed in 1% formaldehyde at room temperature for 10 min. 125 mM glycine was added for 5 min to quench unreacted aldehydes. Cells were washed twice with ice-cold phosphate-buffered saline containing protease inhibitors (Protease Inhibitor Mixture II, Upstate Group), scraped, and collected by centrifugation at 4 °C. Cells were resuspended in SDS lysis buffer containing protease inhibitors, incubated for 10 min on ice, and sonicated four times for 10 s at 8 watts to shear DNA. After sonication, the lysate was centrifuged at 13,000 rpm for 10 min at 4 °C. The supernatant was diluted in ChIP dilution buffer (0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, and protease inhibitors). Immunoprecipitation used antibodies to Sp1 (Upstate Group), Jun (Cell Signaling Technology), and NF
TNF Up-regulates Long MLCK Transcription and Protein Expression in Vitro and in VivoTNF treatment of IFN- -primed Caco-2 intestinal epithelial cell monolayers causes barrier dysfunction via increased myosin II regulatory light chain (MLC) phosphorylation (10, 12). We and others (10, 11) have recently shown that these increases in MLC phosphorylation are accompanied by increased long MLC kinase (MLCK) protein expression. Typically, a 1-2-fold increase in MLCK protein, as detected by SDS-PAGE immunoblot, is induced by TNF (Fig. 1A; p < 0.02). Quantitative real time RT-PCR analysis shows that this is accompanied by 3.0 ± 0.4-fold increase in long MLCK transcription (Fig. 1B; p < 0.05).
To determine whether these TNF-induced increases in MLCK transcription and expression also occur in vivo, mice were injected intraperitoneally with recombinant murine TNF. Jejunal epithelial cells were isolated 4 h after TNF injection and analyzed by SDS-PAGE immunoblot and quantitative real time RT-PCR. MLCK protein content of jejunal epithelial cells increased 4.2 ± 0.5-fold over this period (Fig. 1C, p < 0.01) and MLCK mRNA transcript number increased 3.4 ± 0.8-fold over the same period (Fig. 1D; p < 0.01). Thus, TNF activates long MLCK transcription both in vivo and in vitro. Given that increased MLCK expression is associated with barrier dysfunction (10) and has been observed in patients with inflammatory bowel disease (17), we sought to identify the regulatory elements that control long MLCK expression. Identification of Multiple Long MLCK 5'-Untranslated Regions and Alternative Transcriptional Start SitesThe data above show that long MLCK expression is transcriptionally up-regulated by TNF. We therefore aimed to define the long MLCK promoter. Although the position of the MLCK transcriptional start site has been proposed based on models of gene structure (22), newly identified cDNA sequences (e.g. BC064695 [GenBank] ) that extend beyond the proposed transcriptional start site have raised uncertainty regarding the accuracy of this identification. We therefore performed 5'-RACE on mRNA isolated from Caco-2 cells using a long MLCK 3'-PCR primer within the coding region of exon 3. Two reaction products were identified and sequenced (DQ642691 [GenBank] and DQ642692 [GenBank] ). BLAST searches against the human genome localized both of these sequences to the long MLCK (MYLK) gene on chromosome 3q21. Neither has been previously reported among human cDNA sequences. Therefore, these sequences each represent a new transcriptional start site and corresponding first exons, exon 1A and 1B, for long MLCK (Fig. 2A). Notably, the translational start site and coding sequences, located within exon 2, were identical for the two transcripts. The portion of exon 3 within each sequence was also identical. Thus exons 1A and 1B represent alternative transcriptional start sites for long MLCK in Caco-2 intestinal epithelial cells.
In Silico Analysis of Putative Long MLCK PromotersThe data above show that long MLCK expression is transcriptionally up-regulated by TNF in both human-derived Caco-2 intestinal epithelial cells and murine intestinal epithelial cells. We took advantage of this to preliminarily characterize sequence upstream of the two 5'-untranslated regions we identified for long MLCK expressed in Caco-2 intestinal epithelial cells. Because TNF-induced transcriptional activation is largely mediated by AP-1 and NF
Identification of Elements Necessary for Transcription from the Human Long MLCK PromoterThe sequence upstream of exon 1A was cloned into a luciferase reporter vector and included four putative AP-1 sites 1115-, 3433-, 3713-, and 3771-bp upstream of the transcriptional start site and two putative NF
To further define the sites of this suppressor activity, a series of deletion mutants were analyzed. The suppressor activity was present in a 4-kb promoter with the -2416- to -1588-bp region deleted, but was partly lost when this deletion was extended to -863 bp. The activity of a (-1715 to -618)-bp construct was similar to the (-2416 to -863)-bp construct. Together with the intermediate activity of the 1-kb promoter, these data suggest that sites between -1588 and -433 bp contribute to the observed suppressor activity. Further analysis of deletion mutants lacking varying lengths of sequence between -2416 and -177 bp demonstrate that these sequences are necessary for unstimulated long MLCK transcription. Thus, together with the 120-bp construct, which extends from -278 to -155 bp, these data show that the region from -278 to -177 bp relative to the transcriptional start site is essential for long MLCK transcription. Human Long MLCK Transcription Requires Two Sp1 Sites To evaluate the role of the -278 to -177-bp region, this sequence was evaluated in silico (Fig. 4A). Although no TATA box was identified, two putative Sp1 sites were present 275- and 218-bp upstream of the transcriptional start site. Site-directed mutagenesis of either site-reduced transcription to only 6.0% ± 0.4% and 7.6% ± 0.5% of the wild-type 4-kb construct, a level similar to that of the promoterless pGL3 vector (Fig. 4B). To determine if Sp1 binds to this DNA region in vivo, ChIP analysis was used. Sp1 was immunoprecipitated from Caco-2 cell nuclear extracts and the associated DNA assessed by PCR amplification. The DNA sequence including the two Sp1 sites, -433 to -201 bp, was specifically immunoprecipitated with anti-Sp1, but not control, antisera (Fig. 4C). This suggests that these sequences are bona fide Sp1 binding sites. Together with the mutagenesis data, these results show that DNA sequence 5' to the long MLCK transcriptional start site binds to Sp1 and that these Sp1 sites are required for long MLCK transcription.
The 4-kb MLCK Promoter Is Responsive to TNFAlthough the data above suggest that only the first 278-bp upstream of the transcriptional start site are required for long MLCK transcription, the preliminary in silico analyses suggested that relevant regulatory sites may be present as much as 4-kb upstream (Fig. 3A). These include NF
The 4-kb MLCK Promoter Is Activated by AP-1 and NF B Major transcription factor signaling pathways used by TNF to induce gene expression include AP-1 and NF B (25). To determine if either of these transcription factors is able to activate transcription from the 4-kb MLCK promoter, cells were co-transfected with the promoter construct and vectors that increase AP-1- or NF B-dependent transcription. AP-1-dependent transcription was activated using a constitutively active JNKK2-JNK1 fusion construct (23). This increased luciferase expression from an AP-1 consensus promoter by 2.6 ± 0.3-fold (Fig. 6A, p < 0.01). The JNKK2-JNK1 fusion construct has no significant activating effect on expression from a promoterless luciferase construct or from a luciferase reporter vector with a consensus NF B promoter (Fig. 6A). When MLCK promoters were analyzed, the JNKK2-JNK1 fusion construct did not augment expression from either a 1- or a 2-kb MLCK promoter (Fig. 6B), but did increase expression from the 4-kb MLCK promoter reporter by 1.5 ± 0.1-fold (Fig. 6B; p < 0.01). Thus, the 4-kb MLCK promoter is responsive to AP-1 and critical regulatory sequences are present between 2- and 4-kb upstream of the transcriptional start site.
NF
Characterization of AP-1 and NF
To determine if AP-1 is associated with these sites in Caco-2 cells, nuclear extracts were assessed by ChIP. The AP-1 (1), AP-1 (2), and AP-1(3/4) sites were not detected in AP-1 immunoprecipitates from control Caco-2 cells (Fig. 7B). As AP-1 (3) and AP-1 (4) sites are only separated by 58 base pairs, they cannot be resolved by PCR in ChIP assays. When nuclear extracts from IFN- -primed TNF-treated Caco-2 cells were analyzed, AP-1 immunoprecipitates contained more AP-1 (1), AP-1 (2), and AP-1(3/4) site DNA, relative to control cells (Fig. 7B). As AP-1 (2) and AP-1 (3) sites are only separated by 280 base pairs, the ChIP data should be interpreted to indicate that AP-1 (1) as well as at least one of the AP-1 (2), AP-1 (3), and AP-1 (4) sites bind to AP-1 in a TNF-inducible fashion.
EMSA analysis of the two putative NF
Site-directed Mutagenesis of Specific Transcription Factor Binding Sites Ablates Transcriptional ActivationTogether with the responsiveness of the 4-kb promoter to AP-1 and NF B activation by JNKK2-JNK1 and p50-65 fusion proteins, respectively, the EMSA and ChIP data suggest that the transcription factor binding sites identified may be involved in regulation of MLCK transcription. To determine the specific roles of these sites in MLCK transcriptional regulation each site was disrupted by site-directed mutagenesis. Disruption of the AP-1 (1) site resulted in only mild reduction of luciferase expression (Fig. 9A). In contrast, mutagenesis of AP-1 (2), AP-1 (3), or AP-1 (4) sites markedly reduced the ability of JNKK2-JNK1 fusion protein to increase transcription (Fig. 9A). These data indicate that AP-1 sites 2, 3, and 4 are each required for transcriptional regulation of MLCK by AP-1. In contrast, the AP-1 (1) site appears to be at least partially dispensable.
Similar site-directed mutagenesis of the NF B (1) and NF B (2) sites showed that mutation of either site completely blocked transcription by the p50-65 fusion protein (Fig. 9B). This suggests that both NF B binding sites identified are required for MLCK transcriptional activation by NF B. TNF-induced MLCK Promoter Activation Only Occurs in Well Differentiated Intestinal Epithelial MonolayersThe transcription factors involved in TNF-induced MLCK up-regulation have been a subject of controversy, with conflicting results in separate studies using different Caco-2 cell clones grown under different conditions (10, 11). In comparing these studies one obvious difference is the differentiation state of the Caco-2 monolayers used. We used a well differentiated Caco-2BBE subclone (19) grown for at least 2 weeks after confluence to allow for complete epithelial differentiation (10, 27-29). In contrast, others used the less well differentiated Caco-2 parental line (11). We therefore considered the possibility that differences in results obtained could be caused by differences in epithelial differentiation state.
To model the process of intestinal epithelial differentiation, we studied Caco-2BBE monolayers 3 days after reaching confluence, as well as at early, 7 days, and late, 14 days, in the differentiation process. This is a well established model of intestinal epithelial differentiation that is thought to recapitulate the process that occurs in vivo as cells migrate from crypt to villus (8, 28-33). The data show that TNF did not significantly up-regulate transcription from the full-length 4-kb MLCK promoter in undifferentiated monolayers studied after 3 or 7 days (Fig. 10A). In contrast, at 14 days, when monolayers were well differentiated, the 4-kb MLCK promoter was fully responsive to TNF after priming with IFN- (Fig. 10A). This suggests that the signaling pathways activated by TNF must differ between undifferentiated and well differentiated intestinal epithelial cells.
To determine if activation of NF
MLCK-dependent actomyosin regulation is central to control of many essential cellular processes, including contraction, migration, and epithelial barrier function (27, 34-39). In many nonmuscle cells, long and short MLCK are co-expressed from two different promoters within a single gene (2, 3). When both MLCK proteins are expressed in a single cell, short MLCK tends to associate with myosin IIA, but not F-actin, while long MLCK associates with dense F-actin bundles, but not myosin IIA (4). This suggests that, even when expressed in a single cell, long and short MLCK proteins serve unique functions. Some cell types primarily express only long or short MLCK. For example, we have recently shown that long MLCK is the principal MLCK expressed in intestinal epithelial cells (8). Moreover, we have shown that long MLCK is associated with the perijunctional ring of actomyosin and that the activity of long MLCK can regulate tight junction permeability, i.e. epithelial barrier function (8, 27). Similar roles for MLCK have been reported in other epithelial tissues and vascular endothelia (40-42). We have recently shown that MLCK activation is necessary for the loss of barrier function induced by TNF, both in vitro and in vivo (12, 16). This increased MLCK activity is associated with increased MLCK expression (10, 11), and similar increases in MLCK expression and activity are present in intestinal epithelia of inflammatory bowel disease patients (17). Thus, it is likely that inducible long MLCK expression plays an important role in disease pathogenesis. It is, however, impossible to assess the potential therapeutic efficacy of pharmacological agents that modify gene transcription without detailed understanding of the mechanisms that regulate long MLCK expression.
Our data represent the first comprehensive analysis of the elements necessary for human long MLCK transcription. Thus, while we used cultured human intestinal epithelial cells as our model system, the data are likely to have significant implications in many other cell types. Additionally, our data provide new insights into the structure of the long MLCK, or MYLK, gene. We performed the first 5'-RACE analysis to identify the 5'-untranslated region of long MLCK. In doing so we discovered two previously unrecognized exons that are alternatively used as the transcriptional start site. This observation has important implications, as 31 kb of intronic sequence upstream of exon 1B may represent a unique promoter for that transcriptional start site.
Because of the location of potential binding sites for AP-1 and NF
To identify the mechanism by which the 4-kb sequence activated transcription in response to TNF we first asked whether the long MLCK promoter was responsive to NF
We used a combination of EMSA, ChIP, and site-directed mutagenesis approaches to identify 2 NF
These data prompt one to ask why the intestinal epithelium would use two different transcription factor pathways to increase long MLCK expression. What is so different about the undifferentiated and well differentiated Caco-2 monolayers? To understand this, it is important to recognize that undifferentiated monolayers are most like intestinal crypt epithelium while well differentiated monolayers model villus epithelium (28-33). Undifferentiated crypt epithelium is specialized for proliferation and ion secretion. Thus, one might hypothesize that NF In summary, our data identify two unique 5'-untranslated regions corresponding to two novel alternatively utilized exons and transcriptional start sites for human long MLCK. We are also the first to comprehensively characterize the mammalian promoter for long MLCK transcribed from exon 1A. This is of biological and, potentially, therapeutic importance, given the critical and diverse roles of long MLCK in disease. Moreover, the data suggest that the differentiation state of intestinal epithelial, and perhaps other, cells can profoundly influence cytokine-induced transcriptional activation.
* This work was supported in part by Grants DK61931 and DK68271 from the National Institutes of Health, the Crohn's Colitis Foundation of America, The University of Chicago Digestive Disease Center (DK42086), and The University of Chicago Cancer Center (CA14599). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 A Predoctoral Fellow of the National Institutes of Health, The University of Chicago Medical Scientist Training Program Grant (T32 GM07281). 2 To whom correspondence should be addressed: Dept. of Pathology, The University of Chicago, 5841 South Maryland Ave., MC 1089, Chicago, IL 60637. Tel.: 773-702-2433; E-mail: jturner{at}bsd.uchicago.edu.
3 The abbreviations used are: MLCK, myosin light chain kinase; AP-1, activator protein 1; ChIP, chromatin immunoprecipitation; CMF-HBSS, calcium and magnesium free-Hanks balanced salt solution; EMSA, electrophoretic mobility shift assay; IFN-
4 W. V. Graham and J. R. Turner, unpublished observations.
We thank Amanda Marchiando, Le Shen, and Judy Turner for their insightful comments at various stages of these studies.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||